09:01 , Jun 19, 2019 |  BC Extra  |  Financial News

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme...
23:54 , Jan 18, 2018 |  BioCentury  |  Finance

Hatching Pandion

After scouring academia for novel treatment approaches to autoimmune and inflammatory diseases and coming up empty-handed, Polaris Partners formed Pandion Therapeutics Inc. to develop its own platform from the ground up. Backed with a $58...
12:03 , Jan 18, 2018 |  BC Extra  |  Financial News

Pandion raises $58M series A

Pandion Therapeutics Inc. (Cambridge, Mass.) raised $58 million in a tranched series A round co-led by existing investor Polaris Partners and new investors Versant Ventures and Roche Venture Fund. BioInnovation Capital and SR One, also...
16:30 , Apr 14, 2017 |  BC Week In Review  |  Financial News

Sentien completes venture financing

On April 4, cell therapy company Sentien Biotechnologies Inc. (Cambridge, Mass.) raised $12 million in a series A round co-led by Boehringer Ingelheim Venture Fund and BioInnovation Capital. Chiesi Ventures, MBL Venture Capital and Mass...